Ebrahim Zaileen, Yellon Derek M, Baxter Gary F
The Hatter Cardiovascular Institute, University College London, United Kingdom.
Exp Gerontol. 2007 Aug;42(8):807-14. doi: 10.1016/j.exger.2007.04.005. Epub 2007 Apr 24.
Although in experimental hypertension the cardioprotective effects of ischemic preconditioning (PC) appear to be maintained, most studies have examined the short-term hypertension in juvenile animals. However, aging may be an additional factor that influences the effectiveness of PC. The aim of this study was to characterise the effects on PC of LVH and aging simultaneously. Hearts from spontaneously hypertensive rats (SHR) and age-matched normotensive Wistar-Kyoto rats (WKY) were studied. Excised hearts were Langendorff-perfused to give equivalent coronary flow per gram heart weight. The left main coronary artery was occluded for 35 min followed by 120 min reperfusion. Infarct size was determined by tetrazolium staining. Heart size was assessed as left ventricle/body weight ratio (LV/BW). PC was effected with 2 x 5 min periods of global ischemia prior to coronary occlusion. Hearts were studied at 3-4 months (juvenile), 7-8 months (mature) or 12-13 months (aging). LV/BW ratio in SHR increased relative to WKY controls by 20%, 32% and 40% in juvenile, mature and aging hearts, respectively, but ischemic risk zone size was similar in all groups (52-59% of LV). PC was equally effective at limiting infarct size in juvenile and mature SHR and WKY hearts but was ineffective in aging hearts from both WKY and SHR. Since angiotensin-converting enzyme inhibitors enhance sub-threshold PC in normal myocardium, we also examined the action of captopril (Cap) in aging hearts. Additional aging hearts received treatment with Cap 200 microM as an adjunct to PC. Although Cap+PC was able to induce modest protection in aging WKY hearts, this was not seen in aging SHR hearts. We conclude that PC is lost in longstanding hypertension through independent contributions of both hypertension and aging. These findings may have implications for the clinical development of preconditioning-based therapies since elderly patients with longstanding hypertension are at high risk of developing ischemic heart disease.
尽管在实验性高血压中,缺血预处理(PC)的心脏保护作用似乎得以维持,但大多数研究考察的是幼年动物的短期高血压情况。然而,衰老可能是影响PC有效性的另一个因素。本研究的目的是同时表征左心室肥厚(LVH)和衰老对PC的影响。对自发性高血压大鼠(SHR)和年龄匹配的血压正常的Wistar-Kyoto大鼠(WKY)的心脏进行了研究。将离体心脏用Langendorff法灌注,以使每克心脏重量的冠状动脉血流量相等。左冠状动脉主干闭塞35分钟,随后再灌注120分钟。通过四氮唑染色确定梗死面积。心脏大小以左心室/体重比(LV/BW)进行评估。在冠状动脉闭塞前,通过2次5分钟的全心缺血期实现PC。在3 - 4个月(幼年)、7 - 8个月(成熟)或12 - 13个月(衰老)时对心脏进行研究。相对于WKY对照组,SHR的LV/BW比在幼年、成熟和衰老心脏中分别增加了20%、32%和40%,但所有组的缺血危险区大小相似(占左心室的%)。PC在限制幼年和成熟SHR及WKY心脏的梗死面积方面同样有效,但在WKY和SHR的衰老心脏中无效。由于血管紧张素转换酶抑制剂可增强正常心肌中的亚阈值PC,我们还研究了卡托普利(Cap)在衰老心脏中的作用。另外一些衰老心脏接受了200微摩尔/升卡托普利作为PC辅助治疗。尽管Cap+PC能够在衰老的WKY心脏中诱导适度的保护作用,但在衰老的SHR心脏中未观察到这种情况。我们得出结论,在长期高血压中,由于高血压和衰老的独立作用,PC作用丧失。这些发现可能对基于预处理的治疗方法的临床开发具有启示意义,因为患有长期高血压的老年患者发生缺血性心脏病的风险很高。